Trial results

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

NCT02274740 on ClinicalTrials.gov · last registry update 2017-01-30

Stopped early, having planned 2 participants. Completed August 2015. lixisenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

TERMINATED

Phase

P2

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

2

Started

2015-04

Primary completion

2015-08 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)

Conditions studied

Type II Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.